Mr. Ken d'Entremont reports

MEDEXUS AND BRITISH COLUMBIA'S PROVINCIAL HEALTH SERVICES AUTHORITY (PHSA) SUCCESSFULLY COMPLETE AGREEMENT FOR PUBLIC REIMBURSEMENT OF TRECONDYV (TREOSULFAN FOR INJECTION) IN BRITISH COLUMBIA, CANADA

Medexus Pharmaceuticals Inc. has recently completed a listing agreement with British Columbia's Provincial Health Services Authority, a publicly financed health service provider in the Canadian province, for a new approved indication for Trecondyv (treosulfan for injection) to be listed on the B.C. cancer benefit drug list and financed through B.C. Cancer, a part of PHSA that provides a provincewide population-based cancer control program for the residents of British Columbia. B.C. Cancer will reimburse eligible claims made for Trecondyv for eligible patients in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia or myelodysplastic syndromes at increased risk for standard conditioning therapies.

"This important reimbursement milestone is the first of several we expect following the successful completion of the PCPA negotiation process for Trecondyv," said Richard Labelle, Medexus's chief operating officer. "It demonstrates our commitment to seeking and quickly achieving public reimbursement of Trecondyv across Canada, and is yet another important indicator of this product's prospects and potential, both in the Canadian market and, if and when approved by the FDA, the U.S. market as well."

The next step in the Trecondyv public reimbursement process will be for other remaining government organizations to make their respective final decisions on public reimbursement for their regions or jurisdictions. Medexus is committed to continuing to work with these other participating provincial, territorial and federal government organizations to make Trecondyv available as soon as possible through public drug plans for the patients who need it.

About Trecondyv (treosulfan for injection)

Treosulfan is part of a preparative regimen for allogeneic hematopoietic stem cell transplantation, to be used in combination with fludarabine, used in treating eligible patients with acute myeloid leukemia and myelodysplastic syndromes.

Final study results and analysis of the pivotal phase 3 clinical trial of treosulfan conducted by medac GmbH, which was published in the American Journal of Hematology, concluded that the study demonstrates clinically relevant superiority of treosulfan over a widely applied reduced-intensity conditioning busulfan regimen with regard to its primary end point, event-free survival. The publication also includes favourable conclusions on two key secondary end points, finding that overall survival with treosulfan was superior compared with busulfan and that non-relapse mortality for patients in the treosulfan arm was lower than for patients in the busulfan arm. For more information about the study and the publication, including a link to the full publication, see Medexus's June 6, 2022, press release, available in the investors section of Medexus's corporate website.

During the phase 3 clinical trial of treosulfan, treatment emergent adverse events were most commonly reported in the system organ classes, or SOCs, of gastrointestinal disorders, general disorders and administration site conditions, and musculoskeletal and connective tissue disorders. TEAEs of at least CTCAE Grade 3 were reported by 54.8 cent of patients in the treosulfan treatment group. Severe adverse events were reported by 8.5 per cent of patients in the treosulfan treatment group. Over all, TEAEs were reported by 92.6 per cent of patients in the treosulfan treatment group.

For more information about Trecondyv (treosulfan for injection), including important safety information, see the product monograph, which is available on Health Canada's website.

Treosulfan is approved by Health Canada for sale and use in Canada only, and is not intended for export outside of Canada. Medexus makes no representation that treosulfan is appropriate for, or authorized for sale to or use by, persons who are not located in Canada. Treosulfan is currently the subject of a regulatory review process with the U.S. Food and Drug Administration. Medexus holds exclusive commercialization rights to treosulfan in Canada and the United States.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy and dermatology.

We seek Safe Harbor.